A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

NCT07489599 | Not Yet Recruiting Phase 1

• 1 other identifier: QLH2405-101
• Study Type: interventional
• Target: 68
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of QLH2405 injection in healthy participants and participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild Alzheimer's disease.

Conditions

Alzheimer's Disease(AD); Mild Cognitive Impairment (MCI)

Outcome Measures

Primary Outcomes (1)

• Adverse Events (AEs)

  Percentage of Participants with AEs

  Up to approximately 28 weeks

Study Arms (17)

Part A Cohort 1: Dose level 1 of QLH2405

EXPERIMENTAL

Participants will receive a single dose of QLH2405 at dose level 1.

Drug: QLH2405

Part A Cohort 2: Dose level 2 of QLH2405

EXPERIMENTAL

Participants will receive a single dose of QLH2405 at dose level 2.

Drug: QLH2405

Part A Cohort 2: Placebo

PLACEBO COMPARATOR

Participants will receive a single dose of matching placebo to level 2.

Drug: Placebo

Part A Cohort 3: Dose level 3 of QLH2405

EXPERIMENTAL

Participants will receive a single dose of QLH2405 at dose level 3.

Drug: QLH2405

Part A Cohort 3: Placebo

PLACEBO COMPARATOR

Participants will receive a single dose of matching placebo to level 3.

Drug: Placebo

Part A Cohort 4: Dose level 4 of QLH2405

EXPERIMENTAL

Participants will receive a single dose of QLH2405 at dose level 4.

Drug: QLH2405

Part A Cohort 4: Placebo

PLACEBO COMPARATOR

Participants will receive a single dose of matching placebo to level 4.

Drug: Placebo

Part A Cohort 5: Dose level 5 of QLH2405

EXPERIMENTAL

Participants will receive a single dose of QLH2405 at dose level 5.

Drug: QLH2405

Part A Cohort 5: Placebo

PLACEBO COMPARATOR

Participants will receive a single dose of matching placebo to level 5.

Drug: Placebo

Part A Cohort 6: Dose level 6 of QLH2405

EXPERIMENTAL

Participants will receive a single dose of QLH2405 at dose level 6.

Drug: QLH2405

Part A Cohort 6: Placebo

PLACEBO COMPARATOR

Participants will receive a single dose of matching placebo to level 6.

Drug: Placebo

Part B Cohort 1: Dose level 3 of QLH2405

EXPERIMENTAL

Participants will receive a single dose of QLH2405 at dose level 3.

Drug: QLH2405

Part B Cohort 1: Placebo

PLACEBO COMPARATOR

Participants will receive a single dose of matching placebo to level 3.

Drug: Placebo

Part B Cohort 2: Dose level 4 of QLH2405

EXPERIMENTAL

Participants will receive a single dose of QLH2405 at dose level 4.

Drug: QLH2405

Part B Cohort 2: Placebo

PLACEBO COMPARATOR

Participants will receive a single dose of matching placebo to level 4.

Drug: Placebo

Part B Cohort 3: Dose level 5 of QLH2405

EXPERIMENTAL

Participants will receive a single dose of QLH2405 at dose level 5.

Drug: QLH2405

Part B Cohort 3: Placebo

PLACEBO COMPARATOR

Participants will receive a single dose of matching placebo to level 5.

Drug: Placebo

Interventions

QLH2405 DRUG

QLH2405 will be administered as specified in each treatment arm.

Part A Cohort 1: Dose level 1 of QLH2405

Placebo DRUG

QLH2405-matching placebo will be administered as specified in each treatment arm.

Part A Cohort 2: Placebo

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntarily participate and sign the informed consent.
• Male or female, aged 18 to 65 years (inclusive).
• Healthy status as confirmed by medical evaluation.
• Body mass index (BMI) of 19-28 kg/m² (inclusive).
• Agree to use effective contraception and have no plans for sperm/egg donation or pregnancy from ICF signing until 9 months post-dose.
• Voluntarily participate and sign the informed consent, able to communicate well with the investigator and complete the trial per protocol.
• Male or female, aged 50 to 85 years (inclusive).
• A diagnosis of mild MCI due to AD or mild AD according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria.
• Has subjective cognitive and memory decline for ≥6 months.
• Confirmation of Alzheimer's disease pathological changes by amyloid PET (Aβ-PET) scan.
• Has one (or more) reliable study partner (s)/adult caregiver(s) can accompany the participant to all visits.
• Agree to use effective contraception and have no plans for sperm/egg donation or pregnancy from ICF signing until 9 months post-dose.

You may not qualify if:

• History of significant diseases, or any existing disease may affect the study or pose an unacceptable risk to the participant.
• Positive for HBsAg, HIV-Ab, Treponema pallidum antibody, or HCV-Ab.
• History of blood donation, significant blood loss (total volume ≥400 mL), or blood transfusion within 3 months prior to screening.
• History of alcohol abuse within 1 year prior to screening; or positive alcohol breath test.
• History of drug abuse and/or substance abuse; or positive drug screening.
• Participation in any drug or medical device clinical trial within 3 months prior to screening.
• Pregnant or lactating women, or women of childbearing potential with a positiveβ-hCG test.
• Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.
• Cognitive impairment or dementia caused by any disease other than AD.
• History of stroke within 6 months prior to screening, or imaging evidence of clinically significant central nervous system diseases.
• History of epileptic seizures or epileptiform abnormalities on EEG within 6 months prior to screening.
• Unstable or severe diseases within 6 months prior to screening that, in the investigator's judgment, make the participant unsuitable for study participation.
• eGFR \<60 mL/min/1.73 m².
• AST or ALT \>3 × upper limit of normal (ULN), or total bilirubin \>2 × ULN.
• Current use or anticipated need during the study period for any medication prohibited by the study protocol.

Sponsors & Collaborators

• Qilu Pharmaceutical Co., Ltd.: lead

MeSH Terms

Conditions

Alzheimer Disease; Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Cognition Disorders

Central Study Contacts

Fangyi Wang, Bachelor

CONTACT

+86-18266419923; fangyi.wang@qilu-pharma.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 18, 2026
• First Posted: March 24, 2026
• Study Start: March 1, 2026
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): March 1, 2027
• Last Updated: March 24, 2026

Record last verified: 2026-03